GeoVax Labs, Inc. (GOVX)
| Market Cap | 26.72M |
| Revenue (ttm) | 276,902 |
| Net Income (ttm) | -20.36M |
| Shares Out | 24.74M |
| EPS (ttm) | -2.97 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 621,836 |
| Open | 1.09 |
| Previous Close | 1.05 |
| Day's Range | 1.06 - 1.12 |
| 52-Week Range | 0.55 - 5.61 |
| Beta | 3.31 |
| Analysts | Buy |
| Price Target | 6.12 (+466.7%) |
| Earnings Date | Nov 9, 2022 |
About GOVX
GeoVax Labs, Inc., a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and cancers using modified vaccinia ankara virus-like particle vaccine platform. It is developing various preventive vaccines against (COVID-19), human immunodeficiency virus (HIV); Zika virus; malaria; and hemorrhagic fever viruses, such as Ebola, Sudan, Marburg, and Lassa, as well as therapeutic vaccines for HIV, chronic Hepatitis B infections, and solid tumor cancers. The company has collaboration and partnership... [Read more...]
Financial Performance
In 2021, GeoVax Labs's revenue was $385,501, a decrease of -78.86% compared to the previous year's $1.82 million. Losses were -$18.57 million, 527.8% more than in 2020.
Financial StatementsAnalyst Forecast
According to 7 analysts, the average rating for GOVX stock is "Buy." The 12-month stock price forecast is 6.12, which is an increase of 466.67% from the latest price.
News
GeoVax to Present at the H.C. Wainwright 24th Annual Global Investment Conference
Company to Provide Updates on Phase 2 Clinical Trials for COVID-19 Vaccine (GEO-CM04S1) and Phase 1/2 Clinical Trial for Advanced Head and Neck Cancer (Gedeptin ® )
GeoVax Announces Addition to Its Board of Directors
Nicole Lemerond, CFA, Brings Healthcare Finance Expertise to the GeoVax Board
GeoVax Labs Stock Is a Monkeypox Meme Play for Bold Traders
GeoVax Labs (NASDAQ: GOVX ) recently released its second-quarter 2022 financial results. Some investors might object to GeoVax's net earnings loss.
7 Monkeypox Vaccine Stocks to Buy Before They Shoot Higher
Monkeypox stocks, our topic for today, have had a mostly mixed performance so far in 2022. It is likely, however, that they could benefit from the similar tailwinds enjoyed by companies, such as Pfizer ...
GeoVax Labs Stock Has a Lot More Than Hype Behind Its Recent Surge
GeoVax Labs (NASDAQ: GOVX ) stock has gone parabolic and it's easy to see why. As the extent of the 2022 monkeypox outbreak keeps getting worse, this virus continues to be at the top of the headlines.
3 Monkeypox Stocks to Buy as Biden Declares Public Health Emergency
The White House has declared monkeypox a public health emergency. Within the last two weeks, California, New York and Illinois making the same declaration already, and many other states are sounding the...
GeoVax Reports 2022 Second Quarter Financial Results and Provides Corporate Update
Advancing Phase 2 Clinical Trials for COVID-19 and Immuno-Oncology
Monkeypox Stocks GOVX, VRAX, SIGA Rocket on Vaccine Shortage Fears
Monkeypox stocks are rallying amid worries about a shortage of vaccines for the illness in the U.S. Additionally, in recent days, New York state, New York City and San Francisco have issued emergency or...
GeoVax Announces Peer-Reviewed Publication in NPJ Vaccines of Preclinical Data for Vaccine Candidate Against Sudan Eb...
ATLANTA, GA, July 28, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire – GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing human vaccines and immunotherapies against infectious diseases and ...
GeoVax to Report Second Quarter 2022 Financial Results on Wednesday, August 3, 2022 and Provide Corporate Update
Conference Call to be Held Wednesday, August 3, at 4:30 p.m. Eastern Time
Monkeypox Stocks SIGA, GOVX, BVNRY, CHMX, EBS Soar on Global Health Emergency
Drugs and vaccines used against smallpox are seen as the first line of defense against the rising tide of monkeypox infections. The post Monkeypox Stocks SIGA, GOVX, BVNRY, CHMX, EBS Soar on Global Heal...
Why Is GeoVax (GOVX) Stock Up 90% Today?
GOVX stock is soaring in early trading after WHO declared monkeypox a global health emergency over the weekend. The post Why Is GeoVax (GOVX) Stock Up 90% Today?
Two Pharma Companies That Will Profit From The MonkeyPox Outbreak
The monkeypox outbreak has affected 780 people since identified on May 13, 2022. Vaccines are key to curtailing the spread of Monekey Pox. Two pharma companies, Geovax Labs Inc. and Emergent Biosolution...
GeoVax to Present at BIO International Convention 2022
Company to Provide Updates on Phase 2 Clinical Trials for COVID-19 Vaccine and Immuno-oncology/Gedeptin®
GeoVax Announces $20 Million Registered Direct and PIPE Offerings Priced at a Premium to Market Under Nasdaq Rules
Atlanta, GA, May 25, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire -- GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company specializing in developing human vaccines and cancer immunotherapies, announc...
GeoVax Receives Notice of Allowance for Cancer Vaccine Patent in China
Atlanta, GA, May 24, 2022 (GLOBE NEWSWIRE) -- IND-Enabling Studies Underway in the United States for MVA-VLP-MUC1 Vaccine Candidate
Why Is GeoVax (GOVX) Stock Up 25% Today?
GOVX stock is jumping on the firm's 2020 statement that the "basis" of its vaccine vector was approved as for monkeypox prevention. The post Why Is GeoVax (GOVX) Stock Up 25% Today?
GeoVax Announces Upcoming Presentations at Scientific Conferences
ATLANTA, GA, May 04, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire –GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing human vaccines and immunotherapies against infectious diseases and ca...
GeoVax Reports 2022 First Quarter Financial Results and Provides Corporate Update
Company Advancing Phase 2 Clinical Trials for COVID-19 and Immuno-Oncology
GeoVax Labs Stock Jumps On US Patent For Malaria Vaccine Candidate
The U.S. Patent and Trademark Office has issued Patent No. 11,311,612 covering GeoVax Labs Inc's (NASDAQ: GOVX) modified vaccinia Ankara (MVA) vector expressing certain antigens from the malaria parasite.
GeoVax Announces Issuance of Malaria Vaccine Patent
GeoVax's Unique Multi-Antigenic Vaccine Approach Designed to Provide Stronger, Broader Protection Against Malaria
GeoVax to Report First Quarter 2022 Financial Results on Wednesday, April 27, 2022 and Provide Corporate Update
Conference call to be held Wednesday, April 27, at 4:30 p.m. Eastern Time
GeoVax to Participate in Expert Panel Discussion on Pan-Corona and Universal Vaccines at the World Vaccine Congress
Company's COVID-19 Vaccine Candidate GEO-CM04S1 Continues to Advance in COVID-19 Phase 2 Clinical Trials While the Experimental Universal Vaccine Candidate GEO-CM02 Demonstrated Single-Dose, 100% Protec...
GeoVax Announces Issuance of Cancer Vaccine Patent
IND-Enabling Studies Underway for MVA-VLP-MUC1 Vaccine Candidate